Drug Trial Radar · NCT05263479
A Study of HS-20089 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
177
Planned (sponsor's estimate)
Start
Jan 5, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai Hansoh Biomedical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20089 is a novel DAR-6 antibody-drug conjugate (ADC) targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20089 in Patients With Advanced Solid Tumors.
Conditions
- Advanced Solid Tumor
Interventions
HS-20089 (Phase Ia:Dose escalation )Drug
Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
HS-20089 (Phase Ib: Dose expansion)Drug
IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose of HS-20089Time frame: 3 weeks after initiation of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.